Aurobindo Pharma Limited (AUROPHARMA) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Aurobindo Pharma Limited (AUROPHARMA) has a cash flow conversion efficiency ratio of 0.082x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (Rs28.85 Billion ≈ $312.01 Million USD) by net assets (Rs350.34 Billion ≈ $3.79 Billion USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see AUROPHARMA market cap overview for the company's overall valuation and market capitalisation.
Aurobindo Pharma Limited - Cash Flow Conversion Efficiency Trend (2004–2026)
This chart illustrates how Aurobindo Pharma Limited's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Aurobindo Pharma Limited Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Aurobindo Pharma Limited ranked by their cash flow conversion efficiency. Explore AUROPHARMA cash flow quality score to measure how well operating cash flow supports reported net income.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Guangxi Guiguan Electric Power Co Ltd
SHG:600236
|
0.114x |
|
Stifel Financial Corporation
NYSE:SF
|
0.022x |
|
Shenzhen Envicool Technology Co Ltd
SHE:002837
|
-0.024x |
|
Max Healthcare Institute Limited
NSE:MAXHEALTH
|
0.076x |
|
BrightSpring Health Services, Inc. Common Stock
NASDAQ:BTSG
|
0.062x |
|
AVIC Jonhon Optronic Technology Co Ltd
SHE:002179
|
-0.036x |
|
SailPoint, Inc. Common Stock
NASDAQ:SAIL
|
0.006x |
|
SARTORIUS (UNSP.ADS)/1/5
F:SRT0
|
0.049x |
Annual Cash Flow Conversion Efficiency for Aurobindo Pharma Limited (2004–2026)
The table below shows the annual cash flow conversion efficiency of Aurobindo Pharma Limited from 2004 to 2026. View AUROPHARMA share price today for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2026-03-31 | Rs378.83 Billion ≈ $4.10 Billion |
Rs55.13 Billion ≈ $596.22 Million |
0.146x | +21.06% |
| 2025-03-31 | Rs326.47 Billion ≈ $3.53 Billion |
Rs39.25 Billion ≈ $424.43 Million |
0.120x | +47.40% |
| 2024-03-31 | Rs298.51 Billion ≈ $3.23 Billion |
Rs24.35 Billion ≈ $263.28 Million |
0.082x | -8.25% |
| 2023-03-31 | Rs268.52 Billion ≈ $2.90 Billion |
Rs23.87 Billion ≈ $258.12 Million |
0.089x | -56.46% |
| 2022-03-31 | Rs245.74 Billion ≈ $2.66 Billion |
Rs50.16 Billion ≈ $542.51 Million |
0.204x | +34.47% |
| 2021-03-31 | Rs219.29 Billion ≈ $2.37 Billion |
Rs33.29 Billion ≈ $360.01 Million |
0.152x | -41.70% |
| 2020-03-31 | Rs168.25 Billion ≈ $1.82 Billion |
Rs43.81 Billion ≈ $473.82 Million |
0.260x | +119.12% |
| 2019-03-31 | Rs138.92 Billion ≈ $1.50 Billion |
Rs16.51 Billion ≈ $178.55 Million |
0.119x | -28.97% |
| 2018-03-31 | Rs116.82 Billion ≈ $1.26 Billion |
Rs19.55 Billion ≈ $211.37 Million |
0.167x | -52.16% |
| 2017-03-31 | Rs93.74 Billion ≈ $1.01 Billion |
Rs32.79 Billion ≈ $354.57 Million |
0.350x | +67.95% |
| 2016-03-31 | Rs68.18 Billion ≈ $737.31 Million |
Rs14.20 Billion ≈ $153.54 Million |
0.208x | -12.75% |
| 2015-03-31 | Rs51.82 Billion ≈ $560.38 Million |
Rs12.37 Billion ≈ $133.76 Million |
0.239x | +39.45% |
| 2014-03-31 | Rs37.76 Billion ≈ $408.34 Million |
Rs6.46 Billion ≈ $69.89 Million |
0.171x | +63.26% |
| 2013-03-31 | Rs26.22 Billion ≈ $283.53 Million |
Rs2.75 Billion ≈ $29.73 Million |
0.105x | -24.48% |
| 2012-03-31 | Rs23.50 Billion ≈ $254.13 Million |
Rs3.26 Billion ≈ $35.28 Million |
0.139x | +1.45% |
| 2011-03-31 | Rs24.49 Billion ≈ $264.85 Million |
Rs3.35 Billion ≈ $36.24 Million |
0.137x | -41.49% |
| 2010-03-31 | Rs18.33 Billion ≈ $198.28 Million |
Rs4.29 Billion ≈ $46.37 Million |
0.234x | +113.93% |
| 2009-03-31 | Rs12.44 Billion ≈ $134.58 Million |
Rs1.36 Billion ≈ $14.71 Million |
0.109x | -22.37% |
| 2008-03-31 | Rs11.27 Billion ≈ $121.91 Million |
Rs1.59 Billion ≈ $17.16 Million |
0.141x | +571.59% |
| 2007-03-31 | Rs8.90 Billion ≈ $96.20 Million |
Rs186.50 Million ≈ $2.02 Million |
0.021x | +289.34% |
| 2006-03-31 | Rs8.17 Billion ≈ $88.39 Million |
Rs-90.50 Million ≈ $-978.72K |
-0.011x | -106.48% |
| 2005-03-31 | Rs7.14 Billion ≈ $77.27 Million |
Rs1.22 Billion ≈ $13.20 Million |
0.171x | +522.70% |
| 2004-03-31 | Rs7.25 Billion ≈ $78.40 Million |
Rs198.90 Million ≈ $2.15 Million |
0.027x | -- |
About Aurobindo Pharma Limited
Aurobindo Pharma Limited, a pharmaceutical company, develops, manufactures, and commercializes generic pharmaceuticals in India, the United States, Europe, and internationally. The company manufactures a range of finished formulation products in various forms, such as oral solids, liquids, injectables for generic pharmaceuticals, branded specialty pharmaceuticals, and active pharmaceutical ingred… Read more